112 related articles for article (PubMed ID: 20853390)
1. Developments in nonsteroidal antiandrogens targeting the androgen receptor.
Liu B; Su L; Geng J; Liu J; Zhao G
ChemMedChem; 2010 Oct; 5(10):1651-61. PubMed ID: 20853390
[No Abstract] [Full Text] [Related]
2. Circumventing anti-androgen resistance by molecular design.
McGinley PL; Koh JT
J Am Chem Soc; 2007 Apr; 129(13):3822-3. PubMed ID: 17348658
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and preliminary investigations into novel 1,2,3-triazole-derived androgen receptor antagonists inspired by bicalutamide.
Altimari JM; Niranjan B; Risbridger GP; Schweiker SS; Lohning AE; Henderson LC
Bioorg Med Chem Lett; 2014 Nov; 24(21):4948-53. PubMed ID: 25301770
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationships of the first ferrocenyl-aryl-hydantoin derivatives of the nonsteroidal antiandrogen nilutamide.
Payen O; Top S; Vessières A; Brulé E; Plamont MA; McGlinchey MJ; Müller-Bunz H; Jaouen G
J Med Chem; 2008 Mar; 51(6):1791-9. PubMed ID: 18303829
[TBL] [Abstract][Full Text] [Related]
5. Computationally identified novel diphenyl- and phenylpyridine androgen receptor antagonist structures.
Söderholm AA; Viiliäinen J; Lehtovuori PT; Eskelinen H; Roell D; Baniahmad A; Nyrönen TH
J Chem Inf Model; 2008 Sep; 48(9):1882-90. PubMed ID: 18712859
[TBL] [Abstract][Full Text] [Related]
6. Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.
Liu B; Geng G; Lin R; Ren C; Wu JH
Chem Biol Drug Des; 2012 Mar; 79(3):300-12. PubMed ID: 22151347
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer.
Kandil SB; McGuigan C; Westwell AD
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374450
[TBL] [Abstract][Full Text] [Related]
8. Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations.
Liu H; An X; Li S; Wang Y; Li J; Liu H
Mol Biosyst; 2015 Dec; 11(12):3347-54. PubMed ID: 26442831
[TBL] [Abstract][Full Text] [Related]
9. Non-steroidal antiandrogens act as AF-1 agonists under conditions of high androgen-receptor expression.
Fuse H; Korenaga S; Sakari M; Hiyama T; Ito T; Kimura K; Kato S
Prostate; 2007 May; 67(6):630-7. PubMed ID: 17342748
[TBL] [Abstract][Full Text] [Related]
10. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
Urushibara M; Ishioka J; Hyochi N; Kihara K; Hara S; Singh P; Isaacs JT; Kageyama Y
Prostate; 2007 Jun; 67(8):799-807. PubMed ID: 17373727
[TBL] [Abstract][Full Text] [Related]
11. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
12. Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: A Survey on Chemical Structures Binding this Fast-Mutating Target.
Ferroni C; Varchi G
Curr Med Chem; 2019; 26(33):6053-6073. PubMed ID: 30209993
[TBL] [Abstract][Full Text] [Related]
13. Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog-Thalidomide PROTACs.
Kim GY; Song CW; Yang YS; Lee NR; Yoo HS; Son SH; Lee SJ; Park JS; Lee JK; Inn KS; Kim NJ
Molecules; 2021 Apr; 26(9):. PubMed ID: 33926033
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer: Could an antimalarial drug delay the onset of CRPC?
Clyne M
Nat Rev Urol; 2013 Jun; 10(6):307. PubMed ID: 23588402
[No Abstract] [Full Text] [Related]
15. Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation.
Liu H; Han R; Li J; Liu H; Zheng L
J Comput Aided Mol Des; 2016 Dec; 30(12):1189-1200. PubMed ID: 27848066
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel androgen receptor antagonists: a hybrid approach of pharmacophore-based and docking-based virtual screening.
Liu J; Liu B; Guo G; Jing Y; Zhao G
Anticancer Drugs; 2015 Aug; 26(7):747-53. PubMed ID: 25933245
[TBL] [Abstract][Full Text] [Related]
17. A comparative assessment of α-lipoic acid N-phenylamides as non-steroidal androgen receptor antagonists both on and off gold nanoparticles.
Henderson LC; Altimari JM; Dyson G; Servinis L; Niranjan B; Risbridger GP
Bioorg Chem; 2012 Feb; 40(1):1-5. PubMed ID: 22196975
[TBL] [Abstract][Full Text] [Related]
18. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
[TBL] [Abstract][Full Text] [Related]
19. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
Quéro L; Giocanti N; Hennequin C; Favaudon V
Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.
Malinowska K; Neuwirt H; Cavarretta IT; Bektic J; Steiner H; Dietrich H; Moser PL; Fuchs D; Hobisch A; Culig Z
Endocr Relat Cancer; 2009 Mar; 16(1):155-69. PubMed ID: 19011039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
